New Agents in Development for Sepsis: Any Reason for Hope?
(2020) Drugs — Vol. 80, n° 17, p. 1751-1761 (2020)
Files
2020_Vignon_Drugs.pdf
Open Access - Adobe PDF
- 820.16 KB
Details
- Authors
Vignon, Philippe 
Laterre, Pierre-François Daix, Thomas François, Bruno
- Abstract
- Sepsis is a syndrome which is defined as a dysregulated host response to infection leading to organ failure. Since it remains one of the leading causes of mortality worldwide, numerous drug candidates have already been tested, and continue to be developed, as potential adjunct therapies. Despite convincing mechanisms of action and robust pre-clinical data, almost all drug candidates in the field of sepsis have failed to demonstrate clinical efficacy in the past two decades. Accordingly, the development of new sepsis drugs has markedly decreased in the past few years. Nevertheless, thanks to a better understanding of sepsis pathophysiology and pathways, new promising drug candidates are currently being developed. Instead of a unique sepsis profile as initially suspected, various phenotypes have been characterised. This has resulted in the identification of multiple targets for new drugs together with relevant biomarkers, and a better understanding of the most appropriate time to intervention. Within the entire sepsis drugs portfolio, those targeting the immune response are probably the most promising. Monoclonal antibodies targeting either cytokines or infectious agents are undoubtedly part of the potential successful therapeutic classes to come.
- Affiliations
Citations
Vignon, P., Laterre, P.-F., Daix, T., & François, B. (2020). New Agents in Development for Sepsis: Any Reason for Hope? Drugs, 80(17), 1751-1761. https://doi.org/10.1007/s40265-020-01402-z (Original work published 2020)